

David N Church

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4606415/publications.pdf>

Version: 2024-02-01

55
papers

4,673
citations

147726

31
h-index

182361

51
g-index

58
all docs

58
docs citations

58
times ranked

6739
citing authors

#	ARTICLE	IF	CITATIONS
1	Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. <i>Lancet, The</i> , 2020, 395, 350-360.	6.3	364
2	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. <i>Modern Pathology</i> , 2015, 28, 836-844.	2.9	343
3	DNA polymerase ϵ and δ exonuclease domain mutations in endometrial cancer. <i>Human Molecular Genetics</i> , 2013, 22, 2820-2828.	1.4	319
4	A panoply of errors: polymerase proofreading domain mutations in cancer. <i>Nature Reviews Cancer</i> , 2016, 16, 71-81.	12.8	292
5	<i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3347-3355.	3.2	249
6	Prognostic Significance of <i>POLE</i> Proofreading Mutations in Endometrial Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, 402.	3.0	229
7	Somatic <i>POLE</i> proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 207-216.	3.7	227
8	Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 1031-1039.	0.8	216
9	Clinicopathological and molecular characterisation of "multiple-classifier" endometrial carcinomas. <i>Journal of Pathology</i> , 2020, 250, 312-322.	2.1	205
10	Interpretation of somatic <i>POLE</i> mutations in endometrial carcinoma. <i>Journal of Pathology</i> , 2020, 250, 323-335.	2.1	203
11	Evaluation of <i>PIK3CA</i> Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 4297-4305.	0.8	181
12	A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 784-796.	1.6	141
13	Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2016, 17, 1543-1557.	5.1	129
14	CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. <i>Oncolmmunology</i> , 2017, 6, e1338230.	2.1	116
15	Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas. <i>Clinical Cancer Research</i> , 2019, 25, 1087-1097.	3.2	113
16	Promises and challenges of adoptive T-cell therapies for solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 1759-1776.	2.9	113
17	Immunological profiling of molecularly classified high-risk endometrial cancers identifies <i>POLE</i> -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. <i>Oncolmmunology</i> , 2017, 6, e1264565.	2.1	102
18	Survivin in Solid Tumors: Rationale for Development of Inhibitors. <i>Current Oncology Reports</i> , 2012, 14, 120-128.	1.8	98

#	ARTICLE	IF	CITATIONS
19	Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. <i>Nature Communications</i> , 2016, 7, 11111.	5.8	83
20	Five endometrial cancer risk loci identified through genome-wide association analysis. <i>Nature Genetics</i> , 2016, 48, 667-674.	9.4	77
21	Somatic <i>POLE</i> exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. <i>Journal of Pathology</i> , 2018, 245, 283-296.	2.1	71
22	Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. <i>Modern Pathology</i> , 2016, 29, 174-181.	2.9	68
23	Extended Survival in Women With Brain Metastases From HER2 Overexpressing Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 250-254.	0.6	66
24	Evaluation of treatment effects in patients with endometrial cancer and <i>POLE</i> mutations: An individual patient data meta-analysis. <i>Cancer</i> , 2021, 127, 2409-2422.	2.0	62
25	Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 635-643.	3.7	60
26	Adjuvant Treatment for <i>POLE</i> Proofreading Domain Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues. <i>Clinical Cancer Research</i> , 2018, 24, 3197-3203.	3.2	50
27	Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or <i>POLE</i> exonuclease domain mutant colon cancer: a phase III randomised study. <i>ESMO Open</i> , 2020, 5, e000638.	2.0	47
28	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. <i>Nature Communications</i> , 2022, 13, 1373.	5.8	47
29	Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 1508-1519.	1.6	45
30	Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage. <i>British Journal of Cancer</i> , 2019, 121, 474-482.	2.9	41
31	Clinical review "Small cell carcinoma of the bladder. <i>Cancer Treatment Reviews</i> , 2006, 32, 588-593.	3.4	39
32	<i>POLE</i> proofreading mutation, immune response and prognosis in endometrial cancer. <i>Oncolmmunology</i> , 2016, 5, e1072675.	2.1	34
33	'Toxgnostics': an unmet need in cancer medicine. <i>Nature Reviews Cancer</i> , 2014, 14, 440-445.	12.8	29
34	Value of Supraregional Multidisciplinary Review for the Contemporary Management of Testicular Tumors. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 152-156.	0.9	25
35	Germline MBD4 deficiency causes a multi-tumor predisposition syndrome. <i>American Journal of Human Genetics</i> , 2022, 109, 953-960.	2.6	23
36	Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002279.	0.5	21

#	ARTICLE	IF	CITATIONS
37	What is the extent of the advantage of video-assisted thoracoscopic surgical resection over thoracotomy in terms of delivery of adjuvant chemotherapy following non-small-cell lung cancer resection?. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2014, 19, 656-660.	0.5	20
38	Vaccination of chemotherapy patientsâ€™ effect of guideline implementation. <i>Supportive Care in Cancer</i> , 2016, 24, 2317-2321.	1.0	17
39	Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 283-296.	1.3	17
40	Cancer predisposition syndromes: lessons for truly precision medicine. <i>Journal of Pathology</i> , 2017, 241, 226-235.	2.1	13
41	The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. <i>British Journal of Cancer</i> , 2021, 124, 786-796.	2.9	11
42	Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape. <i>Journal of Pathology</i> , 2022, 257, 340-351.	2.1	11
43	Changing Practice Evaluationâ€™ Stage 1 Seminoma: Outcomes With Adjuvant Treatment Versus Surveillance: Risk Factors for Recurrence and Optimizing Follow-up Protocolsâ€™ Experience From a Supraregional Center. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 240-244.	0.9	8
44	The MLH1 polymorphism rs1800734 and risk of endometrial cancer with microsatellite instability. <i>Clinical Epigenetics</i> , 2020, 12, 102.	1.8	8
45	Histological and Somatic Mutational Profiles of Mismatch Repair Deficient Endometrial Tumours of Different Aetiologies. <i>Cancers</i> , 2021, 13, 4538.	1.7	8
46	ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective singleâ€™center clinical utility studyâ€™PRECISE study. <i>Cancer Medicine</i> , 2019, 8, 6305-6314.	1.3	6
47	Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. <i>ESMO Open</i> , 2020, 5, e001040.	2.0	6
48	Are NSAIDs Coming Back to Colorectal Cancer Therapy or Not?. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 363-371.	1.0	4
49	Automated assessment of CD8+ T-lymphocytes and stroma fractions complement conventional staging of colorectal cancer. <i>EBioMedicine</i> , 2021, 71, 103547.	2.7	4
50	Tumour-infiltrating CD8+ lymphocytes as a prognostic marker in colorectal cancer: A retrospective, pooled analysis of the QUASAR2 and VICTOR trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3515-3515.	0.8	4
51	Hypermutated Colorectal Cancer and Neoantigen Load. , 2017, , 187-215.		3
52	Neoepitopes and CD3-Positive and CD8-Positive Cells in Polymerase eâ€™Mutated and Microsatellite-Unstable Endometrial Cancers. <i>JAMA Oncology</i> , 2016, 2, 141.	3.4	2
53	A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S35.	0.1	0
54	In Reply: Response to Marioni. <i>Current Oncology Reports</i> , 2013, 15, 3-3.	1.8	0

#	ARTICLE	IF	CITATIONS
55	Abstract IA015: Molecular stratification: Beyond TCGA. , 2021, , .		0